# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-057535
Filing Date
2021-04-29
Accepted
2021-04-29 16:02:20
Documents
3
Period of Report
2021-06-15

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm212689-1_def14a.htm | DEF 14A | 661637
2 | GRAPHIC | tm212689d1-px_01proxybw.jpg | GRAPHIC | 366690
3 | GRAPHIC | tm212689d1-px_02proxybw.jpg | GRAPHIC | 322517
| Complete submission text file | 0001104659-21-057535.txt |  | 1607404

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 21870353
SIC: 2834 Pharmaceutical Preparations